SCHEDULE: Armistice Capital Updates VolitionRx Stake to 9.99%
Beneficial Ownership Report
Armistice Capital, LLC and Steven Boyd have updated their beneficial ownership in VolitionRx Ltd., reporting a collective stake of 9.99% as of March 31, 2025.
Summary
- Armistice Capital, LLC and Steven Boyd, collectively referred to as the 'Reporting Persons,' have filed an Amendment No. 2 to their Schedule 13G.
- The Reporting Persons beneficially own 9,804,352 shares of VolitionRx Ltd. Common Stock.
- This ownership represents 9.99% of the total class of securities.
- Armistice Capital, LLC, a Delaware entity, is the investment manager for Armistice Capital Master Fund Ltd., which directly holds the shares.
- Steven Boyd, a U.S. citizen, is the managing member of Armistice Capital, LLC and is deemed to beneficially own the shares.
- The shares were acquired and are held in the ordinary course of business, not for the purpose of changing or influencing the control of VolitionRx Ltd.
Sentiment
Score: 5
Explanation: This is a neutral, factual disclosure of beneficial ownership and does not contain information that would indicate positive or negative sentiment regarding the company's performance or outlook.
Future Outlook
The filing does not contain any forward-looking statements or guidance regarding the issuer's operations or financial performance.
Industry Context
This filing is a routine disclosure of significant beneficial ownership by an institutional investor, common in the financial industry for transparency regarding large equity stakes. It does not provide insights into broader industry trends or competitive landscape.
Related Party Transactions
- Armistice Capital, LLC acts as the investment manager for Armistice Capital Master Fund Ltd., the direct holder of the shares.
- Steven Boyd is the managing member of Armistice Capital, LLC, establishing a control relationship over the reported shares.
Stakeholder Impact
- Shareholders: Provides transparency regarding a significant institutional ownership stake, which can influence market perception and liquidity.
- Investors: Informs the market about the holdings of a notable investment firm, potentially signaling confidence or a passive investment strategy.
Key Dates
| Date | Description |
|---|---|
| 03/31/2025 | Date of event which requires the filing of this statement, reflecting the beneficial ownership percentage. |
| 05/15/2025 | Date the Schedule 13G/A Amendment No. 2 was signed and filed. |
Keywords
VolitionRx Ltd, Armistice Capital, Steven Boyd, Beneficial Ownership, SEC Filing, Schedule 13G, Common Stock, Institutional Investor
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.